glp-1 agonist alcohol medications get at the heart of addiction: study – WashU Medicine GLP-1 agonists help reduce alcohol
Description
Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron achieved up to 14.7% mean weight reduction [press release]
More recently, clinicians have begun exploring their use in patients with Type 1 diabetes, particularly those with obesity, insulin resistance or features of metabolic syndrome
The three primary outcome measures were intracranial pressure at 2.5 h, 24 h and 12 weeks and alpha set a priori at less than 0.1
Maybe, possibly, we actually have no idea
A peer review file is available
Volz A, Gke R, Lankat-Buttgereit B, Fehmann HC, Bode HP, Gke B
